"Primary Myelofibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
| Descriptor ID |
D055728
|
| MeSH Number(s) |
C15.378.190.636.765
|
| Concept/Terms |
Primary Myelofibrosis- Primary Myelofibrosis
- Myelofibroses, Primary
- Myelofibrosis, Primary
- Primary Myelofibroses
- Bone Marrow Fibrosis
- Bone Marrow Fibroses
- Fibroses, Bone Marrow
- Fibrosis, Bone Marrow
- Myelofibrosis
- Myelofibroses
- Idiopathic Myelofibrosis
- Myeloid Metaplasia
- Metaplasia, Myeloid
- Metaplasias, Myeloid
- Myeloid Metaplasias
- Myelosclerosis
- Myeloscleroses
- Myelosis, Nonleukemic
- Myeloses, Nonleukemic
- Nonleukemic Myeloses
- Nonleukemic Myelosis
- Chronic Idiopathic Myelofibrosis
- Agnogenic Myeloid Metaplasia
- Agnogenic Myeloid Metaplasias
- Metaplasia, Agnogenic Myeloid
- Metaplasias, Agnogenic Myeloid
- Myeloid Metaplasia, Agnogenic
- Myeloid Metaplasias, Agnogenic
- Myelofibrosis With Myeloid Metaplasia
|
Below are MeSH descriptors whose meaning is more general than "Primary Myelofibrosis".
Below are MeSH descriptors whose meaning is more specific than "Primary Myelofibrosis".
This graph shows the total number of publications written about "Primary Myelofibrosis" by people in this website by year, and whether "Primary Myelofibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Primary Myelofibrosis" by people in Profiles.
-
Lopez-Mattei J, Verstovsek S, Fellman B, Iliescu C, Bhatti K, Hassan SA, Kim P, Gray BA, Palaskas NL, Grosu HB, Mamas MA, Faiz SA. Prevalence of pulmonary hypertension in myelofibrosis. Ann Hematol. 2020 Apr; 99(4):781-789.
-
Pizzi M, Gergis U, Chaviano F, Orazi A. The effects of hematopoietic stem cell transplant on splenic extramedullary hematopoiesis in patients with myeloproliferative neoplasm-associated myelofibrosis. Hematol Oncol Stem Cell Ther. 2016 Sep; 9(3):96-104.
-
Gergis U, Kuriakose E, Shore T, Mayer S, Mark T, Pearse R, Schuster M, Feldman E, Roboz G, Ritchie E, Scandura J, Wang H, Zhou XK, Silver RT, van Besien K. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clin Lymphoma Myeloma Leuk. 2016 May; 16(5):297-303.
-
Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant. 2016 Mar; 22(3):432-40.
-
Gross-Davis CA, Heavner K, Frank AL, Newschaffer C, Klotz J, Santella RM, Burstyn I. The role of genotypes that modify the toxicity of chemical mutagens in the risk for myeloproliferative neoplasms. Int J Environ Res Public Health. 2015 Feb 24; 12(3):2465-85.
-
Di Nisio M, Barbui T, Di Gennaro L, Borrelli G, Finazzi G, Landolfi R, Leone G, Marfisi R, Porreca E, Ruggeri M, Rutjes AW, Tognoni G, Vannucchi AM, Marchioli R. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007 Jan; 136(2):249-59.
-
Pullarkat V, Bass RD, Gong JZ, Feinstein DI, Brynes RK. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome. Am J Hematol. 2003 Jan; 72(1):8-12.